Eglumetad

Drug Profile

Eglumetad

Alternative Names: Eglumegad; LY-354740

Latest Information Update: 29 Oct 2009

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Anxiolytics; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Neuroprotection; Panic disorder; Psychotic disorders; Schizophrenia; Seizures; Smoking withdrawal

Most Recent Events

  • 01 Aug 2006 No development reported - Phase-II for Panic disorder in USA (unspecified route)
  • 08 Oct 2003 A study has been added to the Anxiety disorders therapeutic trials section
  • 10 Jun 2003 A preclinical study has been added to the Psychotic disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top